BCC 2021 | Will genomic profiling replace clinical and pathological risk factors in ER+ breast cancer?

Martine Piccart, MD, PhD, Université Libre de Bruxelles, Brussels, Belgium, discusses whether genomic profiling will ever place traditional clinical and pathological risk profiling. Prof. Piccart highlights that while recent trials have demonstrated the significant benefits of genomic profiling, they have also shown that clinical and pathological factors still have value. Moving forward, integrating all three factors into an automated prognostic model may aid the selection of adjuvant therapy in patients with ER+ breast cancer. This interview took place during the 17th St. Gallen International Breast Cancer Conference.